Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

CSL to Invest A$800 Million in Melbourne Vaccine Manufacturing Plant

11/15/2020 | 05:54pm EST

By Stuart Condie

SYDNEY--CSL Ltd. said it will invest more than 800 million Australian dollars (US$581.8 million) in a new influenza vaccine manufacturing plant in Melbourne.

The ASX-listed biotech giant on Monday said the plant will use cell-based technology to produce influenza vaccines for both seasonal and pandemic purposes. The products will go to Australia with capacity to support global markets, CSL said in a statement.

Construction of the plant is expected to commence in 2021, with production online by mid-2026, it said. The Victoria state government will also contribute to the project, CSL said.

"The facility will be an important addition to our global influenza manufacturing supply chain," CSL Chief Executive and Managing Director Paul Perreault said. "Cell-influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production: particularly important in the case of influenza pandemics."

CSL said the investment will come via its Seqirus subsidiary.

The facility will also manufacture a proprietary Seqirus adjuvant, which CSL said is added to some vaccines to improve immune response and to reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly.

Write to Stuart Condie at stuart.condie@wsj.com

(END) Dow Jones Newswires

11-15-20 1753ET

Stocks mentioned in the article
ChangeLast1st jan.
ASX LIMITED 0.53% 71.75 End-of-day quote.-0.35%
CSL LIMITED 1.36% 271.14 End-of-day quote.-4.25%
S&P/ASX 200 0.41% 6770.4 Real-time Quote.1.15%
All news about CSL LIMITED
01/19Australia shares jump 1% on reports Queensland to lift lockdown curbs
RE
01/12Australia blocks Chinese buyout of builder over security concerns -media
RE
01/11Gold miners drag down Australian shares; NZ falls 2%
RE
01/08Australia shares notch best week in 2 months on broader global rally
RE
01/08MARKET CHATTER : CSL to Finish Production of First Batch of AstraZeneca COVID-19..
MT
01/06Australian shares end 1% lower as U.S. runoff results trickle in
RE
01/06Australia shares open lower as domestic virus concerns weigh
RE
2020Australia shares dip on Sydney restrictions, NZ inches down
RE
2020Australian shares track Wall Street declines; NZ flat
RE
2020Australia shares climb as U.S. aid bill passage boosts sentiment, NZ at recor..
RE
More news
Financials (USD)
Sales 2021 10 127 M - -
Net income 2021 2 254 M - -
Net Debt 2021 4 668 M - -
P/E ratio 2021 42,3x
Yield 2021 1,04%
Capitalization 95 134 M 94 930 M -
EV / Sales 2021 9,86x
EV / Sales 2022 9,14x
Nbr of Employees 27 000
Free-Float 100,0%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 228,31 $
Last Close Price 209,10 $
Spread / Highest target 20,1%
Spread / Average Target 9,19%
Spread / Lowest Target -6,67%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
Joy Carolyn Linton Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-4.25%94 930
SAMSUNG BIOLOGICS CO.,LTD.-3.63%47 755
BIOGEN INC.11.84%42 139
ALEXION PHARMACEUTICALS, INC.0.29%34 733
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-10.55%32 676
UCB2.23%19 778